Abbott buys Evalve for up to $410 million
This article was originally published in Scrip
Executive Summary
Abbott is to acquire the 90% of outstanding shares of Evalve that it does not already own for up to $410 million to strengthen its vascular business. Evalve develops devices for minimally invasive repair of cardiac mitral valves.